Thursday, May 19, 2016

BRIEF-Merck KGaA expects to file for first approval of Avelumab in H2

* CEO says expects to file for first approval of Avelumab in

merkel cell carcinoma in H2

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)